| 摘要 |
Obesity is a common clinical problem in most developed nations and is also rapidly becoming a major health concern in developing nations. Overweight individuals frequently suffer from several metabolic disorders such as insul in resistance, type 2 diabetes and dyslipidemia. This invention discloses proof of principle for the role PPA.delta. (also known as .beta.) plays in the development of diet-induced obesity. In accordance with the present inventio n, a new method for treating obesity, insulin resistance and hyperlipidemia through administration of a pharmaceutical composition containing a chemical agent that antagonizes the function of PPAR.delta.(.beta. protein, decreases PPAR.delta.(.beta. gene expression and or transactivation of PPAR.delta.(.beta. target gene expression is disclosed. This invention also proposes that obese, insulin resistant hyperlipidemic patients can be effectively treated with a combination of a PPAR.delta.(.beta. antagonist wi th either an antidiabetic agent or a lipid-lowering agent (or both).
|
